Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Ixchel Pharma, LLC. v. Biogen Inc.
Case Number:
2:17-cv-00715
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
January 26, 2018
Ixchel On Last Legs With Antitrust Claims Against Biogen
A California federal judge on Thursday gave Ixchel Pharma LLC one last chance to accuse Biogen Inc. of entering into an anti-competitive agreement with another company and undermining Ixchel's development of a treatment for a rare neuromuscular disease, holding the latest complaint is just as deficient as its predecessor.
-
September 12, 2017
Judge Dismisses Ixchel's Antitrust Claims Against Biogen
A California federal judge on Tuesday dismissed Ixchel Pharma LLC's claims alleging Biogen Inc. made an anti-competitive agreement to undermine Ixchel's development of a treatment for a rare neuromuscular disease, saying the two companies are not competitors.
-
August 14, 2017
No Cracks In Antitrust Suit Against Biogen, Rival Argues
Ixchel Pharma LLC on Friday told a California federal court it had already suffered financial losses due to rival Biogen Inc.'s alleged anti-competitive scheme to undermine its development of a treatment for a rare neuromuscular disease and asked that its lawsuit be allowed to proceed.
-
May 25, 2017
Biogen Asks Judge To Toss Neurological Drug Antitrust Suit
Biogen Inc. asked a California federal judge to toss an antitrust suit brought by a pharmaceutical research company, arguing Wednesday that the company failed to show how Biogen's decision to enter a patent settlement and license agreement caused any harm to competition.
-
April 04, 2017
Biogen Accused Of Stifling Neurological Drug Competition
Biogen Inc. is facing an antitrust suit in California federal court filed Tuesday by Ixchel Pharma LLC alleging it attempted to hold a monopoly on drug treatments containing dimethyl fumarate, preventing Ixchel from creating a drug for a degenerative neurological disease.